The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Magnetic Drug Targeting--Biodistribution of the Magnetic Carrier and the Chemotherapeutic agent Mitoxantrone after Locoregional Cancer Treatment
Abstract
Magnetic Drug Targeting means the specific delivery of chemotherapeutic agents to their desired targets, e.g. tumors, by using magnetic nanoparticles (ferrofluids) bound to these agents and an external magnetic field which is focused on the tumor. This type of target directed drug injection attempts to concentrate a pharmacologic agent by enhancing its efficacy while simultaneously minimizing deleterious side effects. In previous studies, we have been able to demonstrate the efficacy of this type of localized intraarterial chemotherapy in VX2 squamous cell carcinoma among rabbits [Alexiou, C., Arnold, W., Klein, R.J., Parak, F.G., Hulin, P., Bergemann, C., Erhardt, W., Wagenpfeil, S. and Lübbe, A.S. "Locoregional cancer treatment with Magnetic Drug Targeting", Cancer Res. 60 (2000) 6641-6648]. In the present investigation, we have studied the biodistribution of ferrofluids and chemotherapeutic agent by measuring the amount in the tumor, peritumoral area, various organs and body fluids (e.g. blood and urine), with and without Magnetic Drug Targeting. We compared results to that of administering a chemotherapeutic agent soley. An external magnetic field was directed toward the tumor for 60 min. Biodistribution of ferrofluids in the tumor was investigated using histological cross sections and measured semi-quantitatively using 123I-labeled nanoparticles and quantitatively by the use of radioactive 59Fe-ferrofluids. Mitoxantrone was quantitatively measured using HPLC-analysis. The strength of the external magnetic field was 0.6 Tesla (permanent magnet) in the 123iodine study and 1.7 Tesla (electromagnet) in the 59Fe-study and HPLC-analysis. The concentration of the ferrofluids (FFs) in the tumor region i.e. the tumor tissue and the surrounding area, which was under the influence of an external magnetic field, was found to be much higher than in the absence of one. In contrast to systemic chemotherapy, a much higher concentration of mitoxantrone in the tumor and the peritumoral area (region surrounding the tumor < or = 1 cm), by using only 50% and 20% of the normal dose was seen. Thus, the higher concentration of mitoxantrone could explain the therapeutic efficacy of Magnetic Drug Targeting in treatment of VX2 squamous cell carcinoma in rabbits in our previous studies with the advantage of no adverse clinical side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Locoregional cancer treatment with magnetic drug targeting.
Alexiou, C., Arnold, W. J., Klein, R. J., Parak, F., Hulin, P., Bergemann, C., Erhardt, W. D., Wagenpfeil, S., & Lübbe, A. S. (2000) · PubMed · Cited by 863
Self-citationLübbe, A. S., Bergemann, C., Riess, H. B., Schriever, F., Reichardt, P., Possinger, K., Matthias, M., Dörken, B., Herrmann, F., Gürtler, R., et al. (1996) · PubMed · Cited by 652
Self-citationMicrovascular permeability of normal and neoplastic tissues
Gerlowski, L. E., & Jain, R. K. (1986) · Microvascular Research · doi:10.1016/0026-2862(86)90018-x · Cited by 622
Langer, R. (2001) · Science · doi:10.1126/science.1063273 · Cited by 579
Magnetic Microspheres: A Model System for Site Specific Drug Delivery in Vivo
Widder, K. J., Senyei, A. E., & Scarpelli, D. G. (1978) · Experimental Biology and Medicine · doi:10.3181/00379727-158-40158 · Cited by 454
Preclinical experiences with magnetic drug targeting: tolerance and efficacy.
Lübbe, A. S., Bergemann, C., Huhnt, W., Fricke, T., Riess, H. B., Brock, J., & Huhn, D. (1996) · PubMed · Cited by 397
Self-citationMagnetic drug targeting: biodistribution and dependency on magnetic field strength
Alexiou, C., Schmidt, A., Klein, R., Hulin, P., Bergemann, C., & Arnold, W. (2002) · Journal of Magnetism and Magnetic Materials · doi:10.1016/s0304-8853(02)00605-4 · Cited by 227
Self-citationAlbumin Microspheres as Vehicles for Achieving Specificity in Drug Delivery
Kramer, P. A. (1974) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600631044 · Cited by 201
Widder, K. J., Senyei, A. E., & Ranney, D. F. (1979) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60246-x · Cited by 193
Walter, K. A., Tamargo, R. J., Olivi, A., Burger, P. C., & Brem, H. (1995) · Neurosurgery · doi:10.1227/00006123-199512000-00013 · Cited by 192
Cited by
Reddy, L. H., Arias, J. L., Nicolas, J., & Couvreur, P. (2012) · Chemical Reviews · doi:10.1021/cr300068p · Cited by 2,010
Chertok, B., Moffat, B. A., David, A. E., Yu, F., Bergemann, C., Ross, B. D., & Yang, V. C. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.050 · Cited by 900
Self-citationBiodistribution, Clearance, and Biocompatibility of Iron Oxide Magnetic Nanoparticles in Rats
Jain, T. K., Reddy, M. K., Morales, M. A., Leslie-Pelecky, D. L., & Labhasetwar, V. (2008) · Molecular Pharmaceutics · doi:10.1021/mp7001285 · Cited by 705
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
Iron Oxide Nanoparticles for Magnetically-Guided and Magnetically-Responsive Drug Delivery
Estelrich, J., Escribano, E., Queralt, J., & Busquets, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16048070 · Cited by 532
Metadata
- Authors
- Huenges, E., Parak, F., Alexiou, C., Jurgons, R., Schmid, R. J., Bergemann, C., Henke, J., & Erhardt, W.
- Venue
- Journal of Drug Targeting
- Publisher
- Informa UK Limited
- Published
- 2003-09-01
- Volume
- 11
- Issue
- 3
- Pages
- 139-149
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- OpenAlex
- W2059619902
- Cited by
- 293
- References
- 13
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Magnetic Drug Targeting--Biodistribution of the Magnetic Carrier and the Chemotherapeutic agent Mitoxantrone after Locoregional Cancer Treatment. https://app.cochat.ai/papers/10.1080/1061186031000150791
- The paper
- Huenges, E., Parak, F., Alexiou, C., Jurgons, R., Schmid, R. J., Bergemann, C., Henke, J., & Erhardt, W. (2003). Magnetic Drug Targeting--Biodistribution of the Magnetic Carrier and the Chemotherapeutic agent Mitoxantrone after Locoregional Cancer Treatment. Journal of Drug Targeting. https://doi.org/10.1080/1061186031000150791
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.